Last reviewed by Dr. Dharmender Malik on 13 May 2026 · this article reflects the published evidence and current clinical practice at FMRI Gurugram.
Introduction
The liver receives most of its tumour blood supply from the hepatic artery, while normal liver tissue is fed predominantly by the portal vein. This anatomical quirk is what makes intra-arterial therapies possible: an interventional radiologist can selectively cannulate the hepatic artery branches supplying a tumour and deliver a therapeutic agent that preferentially affects the tumour while largely sparing normal liver. Two such therapies dominate practice: transarterial chemoembolization (TACE), which delivers cytotoxic chemotherapy together with embolic particles, and transarterial radioembolization (TARE), which delivers Yttrium-90-loaded microspheres that emit beta radiation locally over about two weeks.
For hepatocellular carcinoma (HCC) and for liver metastases from neuroendocrine tumours (NETs), both options have a role. Choosing between them is not a matter of which is "better" in the abstract — it is a question of which fits the specific tumour pattern, liver reserve, and clinical situation of the individual patient. This guide walks through the comparison.
How each therapy works
TACE delivers chemotherapy (commonly doxorubicin or cisplatin, often in a lipiodol emulsion or as drug-eluting beads) directly into the tumour-feeding artery, followed by embolic particles that block the artery. The mechanism combines two effects: the chemotherapy reaches a high local concentration in the tumour, and the blockage causes ischaemic necrosis. The treatment effect happens over days.
TARE delivers Y-90 microspheres — tiny glass or resin beads loaded with the beta-emitting radioisotope Yttrium-90 — into the tumour-feeding artery. The microspheres lodge in the small tumour vessels and deliver beta radiation over about two weeks (the half-life of Y-90 is 64.1 hours; therapeutic effect continues for several half-lives). Unlike TACE, TARE is not primarily ischaemic — the microspheres are small enough to lodge in pre-capillary vessels without blocking the main feeding artery, which means normal liver perfusion can continue. The dominant mechanism is radiation, not embolisation.
Where TACE typically fits best
TACE has decades of evidence behind it and remains a standard of care for intermediate-stage HCC (BCLC stage B). It is particularly suited to patients with multifocal HCC confined to the liver, preserved liver function (Child-Pugh A, sometimes Child-Pugh B7), and no major vascular invasion. TACE is typically delivered in repeated sessions, often every six to eight weeks, with response assessed by imaging before the next session.
TACE works well for patients who can return for repeat procedures and tolerate the post-embolisation syndrome that commonly follows treatment — fever, abdominal pain, and transient nausea lasting a few days. The treatment is widely available across India at a lower cost point than TARE, which is also a real-world consideration for many patients and families.
Where TARE typically fits best
TARE has become the preferred option in several specific situations: patients with portal vein tumour thrombus (where TACE is often contraindicated because of the risk of liver infarction); patients with larger, solitary HCC tumours where radiation segmentectomy or radiation lobectomy can achieve complete pathological response; patients who cannot tolerate repeated procedures and would benefit from a single-session approach; and patients being considered for liver transplant where TARE is used as a bridge or as part of downstaging.
For NET liver metastases, TARE is increasingly used because the radiation effect is well-tolerated, the side-effect profile is favourable, and a single treatment can affect a large tumour burden. The DOSISPHERE-01 trial demonstrated that dosimetry-guided TARE can produce response rates of around 70 percent in HCC, and analogous experience exists in NET liver metastases though without a comparable randomised trial.
Side-effect profiles
The two treatments have distinct side-effect patterns. After TACE, post-embolisation syndrome (fever, right-upper-quadrant pain, nausea, fatigue) is expected and usually lasts three to seven days. Some patients experience a temporary deterioration in liver function tests. Less commonly, hepatic artery damage, biliary complications, or non-target embolisation can occur.
After TARE, fatigue is the most common complaint and can last a few weeks. Post-embolisation syndrome is generally milder than after TACE. The treatment-specific risks of TARE relate to radiation to non-target organs: radiation-induced liver disease (rare in modern dosimetry-guided practice), radiation pneumonitis (from lung shunting, which is screened for with a pre-treatment Tc-99m MAA scan), and radiation gastritis or duodenitis (from non-target microsphere deposition, also screened for and mitigated by pre-planning). These complications are uncommon when the pre-treatment workup is thorough.
The OMT framework: how we decide
At FMRI, the choice between TARE and TACE is made within an Optimal Medical Therapy (OMT) multidisciplinary review that brings together the hepatologist, interventional radiologist, nuclear medicine physician, oncologist, and (for transplant candidates) the transplant surgeon. The review considers the tumour pattern (focal vs multifocal, size, location), the underlying liver function (Child-Pugh status, MELD score), the vascular anatomy (portal vein status, hepatic artery anatomy from a pre-treatment angiogram or CT angiogram), the patient's overall fitness, the transplant or surgical pathway if applicable, and the patient's own preferences after full informed-consent discussion.
This is not a checklist that produces a single answer — it is a structured conversation that produces an individualised plan. Sometimes the right answer is TARE; sometimes it is TACE; sometimes it is a combination across different tumours within the same liver; and sometimes the right answer is neither, with systemic therapy or transplant taking priority.
Where this leaves you as a patient
If you are considering either TARE or TACE, the most important step is to ensure your case is reviewed by a multidisciplinary team that has experience with both — and that the team explains why one is being recommended over the other (or why both are options). Bring recent imaging (a multiphase CT or MRI of the liver, ideally within the last six weeks), recent liver function tests, the underlying diagnosis (HCC vs NET metastases, with histology if available), and any prior treatments. With that information on the table, an individualised recommendation is straightforward.
The cost point is a real consideration in India: TACE is typically in the range of INR 1.5 to 3.5 lakh per session (with multiple sessions usually planned), while TARE is typically a single procedure in the range of INR 9 to 14 lakh. The choice should not be driven by cost alone, but it is sensible to have the cost picture clear from the start.
For patients & referring clinicians
Frequently asked questions
Q01
What is the main difference between TARE and TACE?
TACE delivers chemotherapy directly into the tumour-feeding artery and then blocks the artery, causing both chemotherapy effect and ischaemic necrosis. TARE delivers Y-90 microspheres that lodge in tumour vessels and deliver beta radiation locally over about two weeks; it is primarily a radiation therapy rather than an ischaemic one. Both are delivered by an interventional radiologist via the hepatic artery, but their dominant mechanisms — chemotherapy plus embolisation versus targeted radiation — are different.
Q02
Which is better for HCC?
Neither is universally better — it depends on the tumour pattern and the patient. TACE has strong evidence for intermediate-stage multifocal HCC with preserved liver function and is widely used. TARE is preferred in several specific situations: portal vein tumour thrombus, larger solitary tumours where radiation segmentectomy is possible, transplant bridging, and patients who cannot tolerate repeated procedures. A multidisciplinary review of the individual case decides which fits best.
Q03
Which is better for liver metastases from neuroendocrine tumours?
For NET liver metastases, TARE is increasingly favoured because the radiation effect is well-tolerated, the side-effect profile is milder than TACE, and a single treatment can affect a large tumour burden. That said, in some patterns of NET metastases — particularly very focal disease in patients with good liver reserve — TACE remains a reasonable option. The choice is made in a multidisciplinary review that includes consideration of systemic options such as PRRT, somatostatin analogues, and targeted therapy.
Q04
Can I have both TARE and TACE?
Yes, in some situations. Sequential use of one therapy after the other is well-described, particularly when the first treatment has produced a partial response and additional therapy is needed for residual or new tumour. Combination on the same day is not standard. The decision to use both, and in what sequence, is made in a multidisciplinary review based on tumour response and liver function.
Q05
What is post-embolisation syndrome?
Post-embolisation syndrome is a cluster of symptoms — fever, right-upper-quadrant pain, nausea, fatigue — that commonly follows TACE and, to a milder degree, TARE. It reflects the inflammatory response to the treatment and typically resolves within three to seven days. It is managed with paracetamol or other analgesia, antiemetics, hydration, and rest. Severe post-embolisation syndrome is uncommon but is a reason to remain in hospital observation for an extra day or two.
Q06
What is the cost of TARE and TACE in India?
Indicative pricing at FMRI Gurugram: TACE is typically in the range of INR 1.5 to 3.5 lakh per session, with multiple sessions usually planned (so a complete course often totals INR 4 to 10 lakh). TARE is typically a single procedure in the range of INR 9 to 14 lakh. Final pricing depends on the procedural complexity, imaging requirements, and length of hospital stay; we provide a transparent quote after the pre-treatment planning is complete.
Q07
Will I need to stay in hospital?
Both treatments are typically performed as inpatient procedures with a one-to-two-night hospital stay. TACE patients are observed overnight for post-embolisation syndrome management. TARE patients are observed for a similar period, with radiation safety precautions during the stay (these are minor and your nuclear medicine team will explain them clearly). Most patients are discharged the day after the procedure with detailed home-care instructions.
Citations & references
Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
Lancet Gastroenterol Hepatol. 2021;6(1):17-29.
ReferenceSalem R, Johnson GE, Kim E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
Hepatology. 2021;74(5):2342-2352.
Reference
About the Author
Dr. Ishita B. Sen
MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York
Director and Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited (TPPL). Two decades of clinical practice in PSMA imaging and PSMA-directed radioligand therapy, with one of the largest Indian institutional experiences in Lu-PSMA.